Compass Therapeutics: Canaccord Recommends Buy with Nearly 90% Price Potential!
Reading Time: 3 minutes
Compass Therapeutics (CMPX) is a biotech company focused on developing innovative immunotherapies against cancer. Currently, the company's primary focus is on its leading product candidate, Tovecimig (CTX-009), a bifunctional antibody targeting both the tumor-associated marker PD-1 and B7-H4. This is a specialized antibody designed to block two different signaling pathways that cancer cells use to evade the immune system and grow. It simultaneously targets DLL4 and VEGF-A. The current focus is on treating biliary tract carcinoma (a form of liver...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
